(People's Daily Health Client Gao Ruirui)
Since March, the disclosure of the 2021 annual reports of domestic listed pharmaceutical companies has ushered in a peak. According to the incomplete statistics of the People's Daily health client, 45 listed pharmaceutical and biological enterprises have released annual reports, including Kangtai Biological, Dongguang Pharmaceutical, WuXi AppTec, Yongan Pharmaceutical, Teyi Pharmaceutical, Wantai Biological, etc.
Judging from the disclosed announcements, some testing, chemical and pharmaceutical related enterprises have benefited from the impact of factors such as special periods, and the annual performance of 2021 will achieve higher growth.
The People's Daily health client combed the annual report data and found that among the 45 listed pharmaceutical companies, 9 had a net profit growth of more than 100%, 19 had a net profit growth of 0-100%, and 15 had a net profit decline. In the 2021 annual reports disclosed by major pharmaceutical companies, the net profits of 8 enterprises, including Jianmin Group, Teyi Pharmaceutical, Jincheng Pharmaceutical, Lisheng Pharmaceutical, Jimin Medical, Nano Technology, Rongchang Biologics and Wantai Biologics, increased by more than 100%.
However, in the disclosed annual report, the biggest winner is Jimin Medical, which benefited from the demand for covid-19 testing and vaccination, which has enabled Jimin Medical to achieve 22-fold growth. According to the 2021 performance report released by the company on March 24, the company's operating income increased by 26% year-on-year to 1.1 billion yuan during the reporting period, and the net profit was 1.47 billion yuan, and the deduction of non-net profit was 1.1 billion yuan, an increase of 2205.39% year-on-year.
Lisheng Pharmaceutical temporarily ranked second with a net profit growth rate of 1317.3%, according to the 2021 annual report released on March 25, the operating income achieved during the reporting period was 1.092 billion yuan, down 4.29% year-on-year, and the net profit attributable to the shareholders of the listed company was 122 million yuan, an increase of 1317.31% year-on-year. For the rise in performance, Lisheng Pharmaceutical said that in the context of the comprehensive promotion of the procurement policy, the company's key varieties and general drug varieties are selling steadily, and the sales volume of natraparin calcium injection has increased by a large year-on-year.
In addition, on April 13, Kangtai Bio released its annual report, the company achieved operating income of 3,687,226,200 yuan, an increase of 63.07% year-on-year; total realized profit of 1,454,523,800 yuan, an increase of 88.31% year-on-year; net profit attributable to shareholders of listed companies of 1,284,059,400 yuan, an increase of 89.06%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 1,211,259,800 yuan, an increase of 95.23% year-on-year. Kangtai Bio said that during the reporting period, the company attaches importance to R & D investment and technical cooperation, market-oriented, continues to strengthen product research and development efforts and international cooperation, and promotes the launch and sales of new products.
In addition to the above-mentioned enterprises, among the pharmaceutical companies that have disclosed the annual report, a number of Chinese medicine enterprises have also published "report cards", benefiting from the state's favorable policies for the development of traditional Chinese medicine, and many traditional Chinese medicine enterprises such as Kunpharm Group and Baiyun Mountain have achieved performance growth.
